Bispecific antibody · Immune activation, directed at CD19 and CD47 · developed by TG Therapeutics
Phase 1Most advanced trial (none active)
1Registered trials
What is Zeripatamig?
Zeripatamig is a bispecific antibody built from two single-chain variable fragments, one binding CD19 on B cells and one binding CD47. By blocking CD47 from engaging SIRPalpha, it promotes macrophage phagocytosis of CD19/CD47-expressing malignant B cells and induces antibody-dependent cellular cytotoxicity. It is studied in B-cell lymphomas and chronic lymphocytic leukemia.
Summary written with AI from the sources listed at the end of this page.
At a glance
Also known as
TG-1801, NI-1701
Drug type
Bispecific antibody
Targets
CD19, CD47, SIRPalpha (SIRPA) (binding partner it blocks)
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.